)
Visual
test
Emcure Pharmaceuticals
Emcure Pharmaceuticals (EMCURE) investor relations material
Emcure Pharmaceuticals Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary4 Feb, 2026
Executive summary
FY26 Q3 marked the first year of a 5-year strategic roadmap focused on higher revenue growth, improved margins, and value creation.
Reported consolidated revenue from operations of Rs 2,363 crore for Q3FY26, up 20.4% year-over-year and 4.1% sequentially from Q2FY26.
Profit after tax (PAT) for the quarter was Rs 231 crore, a 48.2% increase year-over-year, with EBITDA at Rs 460 crore, up 27.2% year-over-year.
Entered an exclusive partnership with Novo Nordisk to launch semaglutide (Poviztra®), gaining first-mover advantage in a high-growth therapy area and strengthening presence in weight management.
Strong positioning in both chemistry and biotech, with a robust biotherapeutics portfolio and government support for biologics.
Financial highlights
Revenue grew 20.4% year-over-year to INR 2,363 crore in Q3 FY26.
Domestic business up 15.4% to INR 1,025 crore; international business up 24.5% to INR 1,338 crore.
Europe revenue rose 29.6% to INR 464 crore, Canada up 12.8% to INR 397 crore, and emerging markets up 30.7% to INR 477 crore.
Gross margin at 59.3% (down from 60.1% YoY), mainly due to business mix and in-licensing impact.
EBITDA grew 27.2% to INR 460 crore; EBITDA margin expanded to 19.5% (from 18.4% YoY).
PAT rose 48% to INR 231 crore; adjusted PAT (ex-Labor Code) up 65% to INR 260 crore.
Net debt at INR 1,203 crore, expected to peak at INR 1,500 crore and reduce to zero by FY28.
Outlook and guidance
Expecting low- to mid-teens compounded annual growth rate (CAGR) over the next 3-5 years.
EBITDA margin targeted to improve by 300-400 bps over 3-5 years, reaching 23-24%.
Gross margin for FY26 expected around 60%, with international business growth potentially diluting margins slightly.
Capex guidance of INR 300-400 crore per year for the next 2-3 years.
Management remains focused on margin improvement and strong growth through investments in R&D, people, and differentiated product launches.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- MCK
Q3 revenue up 11%, adjusted EPS up 16%, and fiscal 2026 EPS guidance raised to $38.80–$39.20. - ASGN
Q4 revenue hit $980.1M; rebranding and $290M Quinnox acquisition to drive digital growth. - MC
Record 2025 revenue and earnings growth, strong capital returns, and new $300M buyback. - RM
Record net income, revenue, and portfolio growth with improved efficiency and strong outlook. - SNAP
Q4 2025 revenue up 10%, net income $45M, MAUs 946M, and $500M buyback announced. - CPAY
Record 2025 growth and strong 2026 guidance driven by Corporate Payments and capital deployment. - WOLF
Q2: $168M revenue, 50% AI data center growth, $1.3B cash, and negative margins. - GAIN
Net investment income rose, but NAV per share fell on unrealized losses; distributions stayed stable. - GAIN$42.3M realized gains and $7.3M net investment income, but NAV per share fell to $12.49.
- SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks remain.
Next Emcure Pharmaceuticals earnings date
Q4 25/2622 May, 2026
Emcure Pharmaceuticals
Next Emcure Pharmaceuticals earnings date
Q4 25/2622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company involved in the development, manufacturing, and marketing of a broad range of pharmaceutical products. Emcure’s product portfolio includes prescription medicines, biologics, and over-the-counter products, covering therapeutic areas such as cardiology, oncology, nephrology, and anti-infectives. The company operates manufacturing facilities in India and has a significant presence in both domestic and international markets. The company is headquartered in Pune, India.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage